The cumulative evidence of aberrantly increased activity of the primary p53 inhibitor MDM2 in GBM [11], [12] prompted us to examine the effects of targeted inhibition of the MDM2-p53 interaction by the spiro-oxindole analogue ISA27, a recently described small-molecule inhibitor of MDM2 [26]. This evidence concerns the gene TP53 and glioblastoma.